Source: Eur Respir J 2008; 31: 625-632
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Athanassa Z., Siempos I. I., Falagas M. E.. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31: 625-632

Member's Comments

No comment yet.

Related content which might interest you: Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistance Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant staphylococcus aureus (CA-MRSA) Source: Eur Respir J 2007; 30: Suppl. 51, 407s Year: 2007 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP) Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005